Back to top

BioNTech (BNTX)

(Delayed Data from NSDQ)

$348.00 USD


+43.24 (14.19%)

Updated Nov 26, 2021 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
5Strong Sell3.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Wall Street Tumbles on Resurgence of Coronavirus

Wall Street Tumbles on Resurgence of Coronavirus.

Mark Vickery headshot

Black Friday Meets "Black Friday:" New Covid Variant Hits Markets

A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids

FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.

J&J (JNJ) Gets First Full Approval for COVID Jab in Canada

Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.

Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year

Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

Stock Market News for Nov 22, 2021

Wall Street closed mixed on Friday to end a choppy week.

FDA Gives Authorization to Two COVID-19 Boosters

FDA Gives Authorization to Two COVID-19 Boosters

Mark Vickery headshot

FDA Authorizes Covid Boosters; New Fed Chair Soon?

Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."

Kinjel Shah headshot

3 Big Pharma Outperformers to Watch Out For in the Near Term

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Daniel Laboe headshot

The Stock Market Rally Is Back In High Gear

All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?

BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates

Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.

Better-Than-Expected Private Payrolls in October

Better-Than-Expected Private Payrolls in October.

Mark Vickery headshot

ADP: 571K New Private-Sector Jobs, Better than Expected

571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.

Nalak Das headshot

5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone

We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $274.32, moving -1.58% from the previous trading session.

How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Stock Market News for Nov 1, 2021

Wall Street closed higher on Friday despite weak earnings results of a couple of technology behemoths.